AU2001246657A1 - Use of analogues of superoxide dismutase for treating hepatocellular insufficiencies - Google Patents

Use of analogues of superoxide dismutase for treating hepatocellular insufficiencies

Info

Publication number
AU2001246657A1
AU2001246657A1 AU2001246657A AU4665701A AU2001246657A1 AU 2001246657 A1 AU2001246657 A1 AU 2001246657A1 AU 2001246657 A AU2001246657 A AU 2001246657A AU 4665701 A AU4665701 A AU 4665701A AU 2001246657 A1 AU2001246657 A1 AU 2001246657A1
Authority
AU
Australia
Prior art keywords
insufficiencies
superoxide dismutase
analogues
treating hepatocellular
hepatocellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001246657A
Inventor
Frederic Batteux
Pierre-Jacques Ferret
Bernard Weill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris 5 Rene Descartes
Original Assignee
Universite Paris 5 Rene Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris 5 Rene Descartes filed Critical Universite Paris 5 Rene Descartes
Publication of AU2001246657A1 publication Critical patent/AU2001246657A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention concerns the use of a compound having a superoxide dismustase activity, in particular a non-peptide analogue of the superoxide dismutase to obtain a medicine for preventive or curative treatment of hepatocellular insufficiency. Said medicine can be used in particular for treating hepatocellular insufficiencies of toxic or viral origin.
AU2001246657A 2000-03-28 2001-03-28 Use of analogues of superoxide dismutase for treating hepatocellular insufficiencies Abandoned AU2001246657A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0003887A FR2806911B1 (en) 2000-03-28 2000-03-28 USE OF SOD MIMETICS IN THE TREATMENT OF HEPATOCELLULAR DEFICIENCIES
FR0003887 2000-03-28
PCT/FR2001/000939 WO2001072327A2 (en) 2000-03-28 2001-03-28 Use of analogues of superoxide dismutase for treating hepatocellular insufficiencies

Publications (1)

Publication Number Publication Date
AU2001246657A1 true AU2001246657A1 (en) 2001-10-08

Family

ID=8848555

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001246657A Abandoned AU2001246657A1 (en) 2000-03-28 2001-03-28 Use of analogues of superoxide dismutase for treating hepatocellular insufficiencies

Country Status (9)

Country Link
US (1) US20030118577A1 (en)
EP (1) EP1267881B1 (en)
JP (1) JP2003528152A (en)
AT (1) ATE303151T1 (en)
AU (1) AU2001246657A1 (en)
CA (1) CA2404077A1 (en)
DE (1) DE60113078T2 (en)
FR (1) FR2806911B1 (en)
WO (1) WO2001072327A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) * 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
KR20110065549A (en) * 2008-10-03 2011-06-15 샬롯테-맥클렌버그 하스피털 오쏘러티 두잉 비지니스 에즈 카롤리나스 메디컬 센터 Treatment of hepatitis c infection with metalloporphyrins
AU2014374361B9 (en) 2013-12-31 2019-07-04 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
CN113693189B (en) * 2021-09-28 2023-11-17 中国农业科学院北京畜牧兽医研究所 Application and method of manganese peroxidase for degrading patulin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653670B2 (en) * 1985-10-28 1994-07-20 日研フ−ド株式会社 Side effect reducing agent for chemotherapeutic agents
EP0282899B1 (en) * 1987-03-14 1996-01-10 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Human manganese superoxide dismutase (hMn-SoD)
JPS6490133A (en) * 1987-09-29 1989-04-06 Otsuka Pharma Co Ltd Pharmaceutical preparation for oral administration
JPH01238537A (en) * 1988-03-18 1989-09-22 Toyo Jozo Co Ltd Remedy for hepatic disorder
JPH0420285A (en) * 1990-05-15 1992-01-23 Asahi Chem Ind Co Ltd Sod derivative
CA2072934C (en) * 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5834509A (en) * 1992-12-07 1998-11-10 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
WO1995031197A1 (en) * 1994-05-13 1995-11-23 Monsanto Company Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
DE69813898T2 (en) * 1997-11-03 2004-03-11 Duke University SUBSTITUTED PORPHYRINES
WO2000023568A2 (en) * 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
WO2000043498A2 (en) * 1999-01-19 2000-07-27 University Of North Carolina At Chapel Hill Human liver progenitors
ATE312103T1 (en) * 1999-01-25 2005-12-15 Nat Jewish Med & Res Center SUBSTITUTED PORPHYRINS AND THEIR THERAPEUTIC USES

Also Published As

Publication number Publication date
ATE303151T1 (en) 2005-09-15
WO2001072327A2 (en) 2001-10-04
CA2404077A1 (en) 2001-10-04
WO2001072327A3 (en) 2002-03-28
US20030118577A1 (en) 2003-06-26
EP1267881A2 (en) 2003-01-02
FR2806911B1 (en) 2003-01-10
EP1267881B1 (en) 2005-08-31
DE60113078T2 (en) 2006-07-13
FR2806911A1 (en) 2001-10-05
JP2003528152A (en) 2003-09-24
DE60113078D1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
MY127961A (en) Beta-amino heterocyclic dipetidyl peptidase inhibitors for the treament or prevention of diabetes
MY126527A (en) Novel dihydropyrimidines
AU2003274071A1 (en) Dosage form that is safeguarded from abuse
MXPA02011288A (en) Substituted thioacetamides.
HK1045852A1 (en) Polyurethane solutions containing alkoxysilane structural units
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
TW200510343A (en) Substituted dihydroquinazolines
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
AU2001246657A1 (en) Use of analogues of superoxide dismutase for treating hepatocellular insufficiencies
LT2004074A (en) Matricines metalproteinazes inhibuojanti kompozicija neoplazinems ligoms gydyti
YU11402A (en) New use of docetaxel for treating hepatoma
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of ***e dependency
NZ541231A (en) A method of treatment or prophylaxis of symptoms of herpes viral infection
EP1620061A4 (en) Antiviral agents for the treatment, control and prevention of infections by coronaviruses
HK1045258A1 (en) Glutathione reductase for therapy and prophylaxis of aids
WO2003045428A3 (en) Use of a technically modified cell as a vaccine for treating tumoral disease
WO2002074304A3 (en) Composition containing a gallium (iii) complex and a therapeutically effective cytostatic agent
GR1004434B (en) Use of diflofenac or topically acceptable salt thereof for the treatment of burns
WO2003072047A3 (en) Idothyronine compositions
UA85561C2 (en) Use of cell walls of yeast for treatment or prevention of hyperglycemia, or for stabilization of glycemia
AU3145400A (en) Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin
AP1731A (en) Use of an inhibitor of the renin-angiotensin system for the manufacture of a medicament or prevention of lipodystrophy syndorme.
AU6301398A (en) Arrestable therapeutic viral agent
HUP0402645A2 (en) Pharmaceutical composition comprising a glitazone and 4-oxobutanoic acid, and the use thereof for treating diabetes
DE50112512D1 (en) PHENANTHRIDINE DERIVATIVES AND PHENANTHRIDINE-CONTAINING ANTITUMOROUS MEDICAMENTS